Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL2998 Target Snapshot

P2X purinoceptor 3 · SINGLE PROTEIN · Homo sapiens

Back to Search Search this target Browse approvals Evidence Card
5,238Compounds
109Assays
2Approved Drugs
7,666.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

P2X purinoceptor 3 shows approved-linked disease relevance led by Cough. 5 more disease programs remain visible in the same review block. 3 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt P56373. Start with Cough, then reuse UniProt P56373 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with Cough, then reuse UniProt P56373 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13 3 linked drugs
Open source guide
Disease program
Cough

P2X purinoceptor 3 shows approved-linked disease relevance led by Cough. 5 more disease programs remain visible in the same review block. 3 linked drugs remain visible in the same block.

Start review with Cough because it currently carries approved-linked support. Linked drugs include CAMLIPIXANT, GEFAPIXANT, GEFAPIXANT CITRATE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Approved-linked Open Targets-ready proxy 3 linked drugs
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats P2X purinoceptor 3 as ChEMBL target CHEMBL2998, mapped to UniProt P56373. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
P2X purinoceptor 3
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL2998
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P56373
P2X purinoceptor 3
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether P2X purinoceptor 3 is the right protein anchor across sources, using UniProt P56373 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why Cough is currently framed as approved-linked support. It currently carries 3 linked drugs in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameP2X purinoceptor 3
Target TypeSINGLE PROTEIN
OrganismHomo sapiens
UniProtP56373
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelP2X purinoceptor 3
UniProt AccessionP56373
Component TypeProtein
Sequence Length397 aa

P2X purinoceptor 3

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as P2X purinoceptor 3, mapped to UniProt P56373. Sequence length is 397 aa.

Mapped IDP56373
Review nameP2X purinoceptor 3
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Approved-linked Open Targets-ready proxy

P2X purinoceptor 3 shows approved-linked disease relevance led by Cough. 5 more disease programs remain visible in the same review block.

Approved-linked Approved
Cough
3 linked drugs · 3 direct · 3 efficacy
Linked drugCAMLIPIXANT
Linked drugGEFAPIXANT
Linked drugGEFAPIXANT CITRATE
Approved-linked Approved
Cough
2 linked drugs · 2 direct · 2 efficacy
Linked drugCAMLIPIXANT
Linked drugGEFAPIXANT CITRATE
Clinical signal Phase II
asthma
1 linked drug · 1 direct · 1 efficacy
Linked drugGEFAPIXANT
Clinical signal Phase II
idiopathic pulmonary fibrosis
1 linked drug · 1 direct · 1 efficacy
Linked drugGEFAPIXANT
Clinical signal Phase II
interstitial cystitis
1 linked drug · 1 direct · 1 efficacy
Linked drugGEFAPIXANT
Clinical signal Phase II
osteoarthritis, knee
1 linked drug · 1 direct · 1 efficacy
Linked drugGEFAPIXANT
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with Cough because it currently carries approved-linked support. Linked drugs include CAMLIPIXANT, GEFAPIXANT, GEFAPIXANT CITRATE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseaseCough
Strongest levelApproved-linked
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

2
Approved
1
Phase III
2
Phase II
Assay Mix

Activity Type Distribution

IC507,644.0
KI1.0
EC5021.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL395493 10.32 IC50 0.0481 Preclinical
CHEMBL3910178 9.1 IC50 0.8 Preclinical
CHEMBL1163419 9.05 EC50 0.9 Preclinical
CHEMBL5889467 9.0 IC50 1.0 Preclinical
CHEMBL5843845 9.0 IC50 1.0 Preclinical
CHEMBL5828119 9.0 IC50 1.0 Preclinical
CHEMBL5822127 9.0 IC50 1.0 Preclinical
CHEMBL5813666 9.0 IC50 1.0 Preclinical
CHEMBL5750119 9.0 IC50 1.0 Preclinical
CHEMBL3917952 9.0 IC50 1.0 Preclinical
Distribution

pChEMBL Value Distribution

48
5.0
73
5.5
777
6.0
981
6.5
1449
7.0
2024
7.5
1909
8.0
257
8.5
25
9.0
0
9.5
pChEMBL
Approved Drugs

Approved Drugs

GEFAPIXANT
CHEMBL3716057
Approved 2023
Properties Compare Identifier
Assay Landscape

Assay Landscape

109
Total Assays
5,030
Tested Compounds
2
Assay Types
Binding — 86 assays, 5,030 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 53 807 7.4
single protein format 25 822 7.1
assay format 8 3,401 7.6
Functional — 23 assays, 61 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 16 46 6.5
assay format 7 15 6.0

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine